FSSAI opens three cases against Nestlé India over infant-formula claims

India’s food regulator has initiated three adjudication cases involving claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, alongside a biotin-deficiency issue in a follow-up formula. Nestlé India shares fell more than 2.5% after the development.

— Source publishedFri, 18 Sept, 2026, 13:23 IST·First seen Fri, 18 Sept, 2026, 13:43 IST·Source NDTV Profit

What happened

FSSAI initiated three adjudication cases against Nestle India over promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and a biotin deficiency in

Key facts

  • Three adjudication cases
  • 5 HMOs
  • 2.5% share-price decline
  • Rs 1,332.80 share-price low

Why this matters

The cases reinforce the need for rigorous regulatory diligence in India’s infant-nutrition category, where claim substantiation and quality-control liabilities can materially affect asset value.

What to watch

  • FSSAI notices detailing the alleged violations, applicable Food Safety and Standards regulations, and hearing dates.
  • Any interim direction affecting sales, labeling, advertising or recalls of the named products.
  • Nestlé India disclosure of provisions, legal assessment, product relabeling costs or changes to infant-nutrition guidance.
  • Evidence of widened inspections or notices involving other infant-formula brands.
  • Retailer, e-commerce or pharmacy delistings, promotional pauses, or out-of-stock patterns for the named SKUs.
  • Consumer sentiment and pediatrician/pharmacy feedback indicating substitution toward rival brands.
  • Quarterly commentary on infant-nutrition volume growth, market share and margin impact.
  • Conduct a claim-by-claim legal and scientific review of NAN Excella Pro Stage 1, Lactogen Pro 1 and the affected follow-up formula.
  • Prepare revised labels, digital product pages and retailer point-of-sale materials before adjudication outcomes require changes.
  • Engage FSSAI with substantiation dossiers, batch and formulation records, and a remediation timetable where needed.
  • Pause or tighten consumer-facing messaging that could be interpreted as health, development or nutrient-deficiency claims.
  • Brief pediatric, hospital, pharmacy and modern-trade channels to contain misinformation and preserve availability of compliant inventory.
  • Assess whether similar claims or biotin specifications appear across adjacent Nestlé India nutrition products.

Also reported by